EUVIMEDEUVIMED entdecken
Crossref

An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy

Ali McBride, John Brokars, Sheila Reiss Reddy, Eunice Chang, Marian H Tarbox, Thomas W LeBlanc

Acta Haematologica · 2023

DOI: 10.1159/000530512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2023. Verfasst von Ali McBride und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pleural Effusion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion; however, data regarding its optimal management are limited. We examined treatment patterns and healthcare resource utilization (HCRU) and costs among patients with CML treated with dasatinib who experienced a subsequent pleural effusion.

Methods

Adults with CML and ≥1 pharmacy claim for dasatinib in 2015–2018 who experienced pleural effusion after dasatinib were identified using data from claims databases.

Results

Overall, 123 patients were eligible. After 1 year, of the 38.2% of patients with a dose modification, 72.3% did not switch treatment; among these patients, 70.6% continued treatment. Among patients with a stable dose after pleural effusion (61.8%), 57.9% later switched to another TKI. The mean (SD) duration of dasatinib treatment after pleural effusion was 262.0 (124.0) days for patients with a dose modification versus 149.1 (155.2) days for those with a stable dose (p < 0.001). HCRU and costs were similar between groups.

Conclusion

Dasatinib dose modification after pleural effusion was not always required; however, patients with dose modifications continued therapy for a longer duration with a lower rate of switching to another TKI versus patients who remained on a stable dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositivePleural EffusionAdultHumansDasatinibProtein Kinase InhibitorsCosts and Cost Analysis

Stichwörter der Autor:innen

Chronic myeloid leukemiaHematologicalMalignant hematologymalignancies

Substanzen

DasatinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Bristol Myers Squibb, Princeton, New Jersey, USA.
  • PHAR (Partnership for Health Analytic Research), LLC, Beverly Hills, California, USA.
  • Duke University School of Medicine, Durham, North Carolina, USA.

Zitieren

APA

McBride, A., Brokars, J., Reddy, S. R., Chang, E., Tarbox, M. H., & LeBlanc, T. W. (2023). An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy. Acta Haematologica. https://doi.org/10.1159/000530512

Vancouver

McBride A, Brokars J, Reddy SR, Chang E, Tarbox MH, LeBlanc TW. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy. Acta Haematologica. 2023. doi:10.1159/000530512

BibTeX
@article{McBride2023,
  author = {McBride, Ali and Brokars, John and Reddy, Sheila Reiss and Chang, Eunice and Tarbox, Marian H and LeBlanc, Thomas W},
  title = {An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy},
  journal = {Acta Haematologica},
  year = {2023},
  doi = {10.1159/000530512}
}
Kostenlos starten →